baseline characteristics i-scan multicentre study
| Baseline characteristics, n=107 | N | % |
| Age (median; range 23–85 years) | 67 | |
| Gender (female:male) | 32:75 | 30:70 |
| Performance status | ||
| ECOG 0 | 43 | 40 |
| ECOG 1 | 50 | 47 |
| ECOG 2 | 12 | 11 |
| ECOG 3 | 1 | 1 |
| Preprocedure evaluation (available imaging prior to bronchoscopy | ||
| CT thorax | 92% | |
| PET-CT | 76% | |
| Localisation tumour target lesion | ||
| LUL | 30 | 28 |
| LLL | 9 | 8 |
| RUL | 45 | 42 |
| ML | 10 | 9 |
| RLL | 18 | 17 |
| Clinical TNM stage (v7) prior to bronchoscopy | ||
| Ia | 16 | 15 |
| Ib | 8 | 8 |
| IIa | 10 | 9 |
| IIb | 3 | 3 |
| IIIa | 40 | 37 |
| IIIb | 7 | 7 |
| IV | 23 | 22 |
| Bronchoscopy details | ||
| Sedation for bronchoscopy | ||
| None | 15 | 14 |
| Midazolam (mean dose: 4.72±0.4 mg, range 1.3–9.0 mg) | 25 | 23 |
| Propofol | 39 | 36 |
| General anaesthesia | 28 | 26 |
| Study procedure time (min) | 11±0.8 | |
| Use of fluoroscopy | 29 | 27 |
| Complications | 10 | 9 |
| Haemorrhage needing topical agents | 5 | 4.7 |
| Severe haemorrhage | 0 | 0 |
| Dyspnoea | 1 | 0.9 |
ECOG, Eastern Cooperative Oncology Group; LLL, left lower lobe; LUL, left upper lobe; ML, middle lobe; PET, positron emission tomography; RLL, right lower lobe; RUL, right upper lobe; TNM, tumour, node, metastases.